<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806311</url>
  </required_header>
  <id_info>
    <org_study_id>HAMCAO12I_1</org_study_id>
    <nct_id>NCT01806311</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg</brief_title>
  <official_title>An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of
      amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A : AUC, Cmax of Candesartan</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Par B : AUC, Cmax of Amlodipine</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PartA: Cmin, tmax, CL/F of Candesartan</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PartB: Cmin, tmax, CL/F of Amlodipine</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>PartA: Candesartan, Candesartan + Amolodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB: Amlodipine, Amlodipine+Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan32mg</intervention_name>
    <arm_group_label>PartA: Candesartan, Candesartan + Amolodipine</arm_group_label>
    <arm_group_label>PartB: Amlodipine, Amlodipine+Candesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine10mg</intervention_name>
    <arm_group_label>PartA: Candesartan, Candesartan + Amolodipine</arm_group_label>
    <arm_group_label>PartB: Amlodipine, Amlodipine+Candesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male, Age 20 to 45

          2. Subject must be willing and able to provide written informed consent to the study.

        Exclusion Criteria:

          1. History of any significant sickness, liver system, gall bladder system, kidney, nerve
             system, respiratory system, blood tumor, endocrine system, urinary system, mental
             disease, muscloskeletal system, immunity system, the ear, nose and throat system and
             cardiovascular system.

          2. History of any significant gastrointestinal system and surgery of gastrointestinal.

          3. History of any significant hypersensitivity to amlodipine, candesartan, aspirin,
             antibiotic.

          4. Over 10 tobaccos a day.

          5. Other condition which in the opinion of the investigator preclude endrollment into the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam national university hospital, Clinical trial center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam national university hospital,clinical trial center</name>
      <address>
        <city>Daejeon</city>
        <state>Chungcheongbul-do</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Male</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

